These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1775 related items for PubMed ID: 15748904

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.
    Cytometry A; 2005 Oct 01; 67(2):161-71. PubMed ID: 16163699
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L, Montero JC, Esparís-Ogando A, Pandiella A.
    Cancer Res; 2005 Aug 01; 65(15):6801-10. PubMed ID: 16061662
    [Abstract] [Full Text] [Related]

  • 11. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.
    Cancer Res; 1996 Mar 15; 56(6):1457-65. PubMed ID: 8640840
    [Abstract] [Full Text] [Related]

  • 12. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 15; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 14. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM.
    Cancer Res; 2005 Jan 15; 65(2):473-82. PubMed ID: 15695389
    [Abstract] [Full Text] [Related]

  • 15. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 16. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X, Yeung TK, Wang Z.
    Biochem Biophys Res Commun; 2000 Nov 02; 277(3):757-63. PubMed ID: 11062025
    [Abstract] [Full Text] [Related]

  • 17. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM.
    Oncogene; 2003 Nov 06; 22(50):8178-86. PubMed ID: 14603258
    [Abstract] [Full Text] [Related]

  • 18. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 19. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY.
    Breast Cancer Res Treat; 2008 Sep 07; 111(2):241-50. PubMed ID: 17955362
    [Abstract] [Full Text] [Related]

  • 20. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.